DNA Mosaic env vaccine

DNA Mosaic env vaccine is an investigational HIV-1 vaccine candidate consisting of DNA plasmids encoding bioinformatically designed 'mosaic' HIV-1 envelope (env) proteins. Developed by researchers at the National Institute of Allergy and Infectious Diseases (NIAID) and Beth Israel Deaconess Medical Center, the mosaic sequences are engineered to provide broad coverage against the high genetic diversity of global HIV-1 strains by incorporating common T-cell epitopes. In clinical trials, such as HVTN 096 and HVTN 106, this DNA vaccine is typically used as a priming agent in a prime-boost regimen, followed by viral vector boosts like MVA-CMDR or NYVAC Mosaic env. The goal of this approach is to elicit both robust cellular and humoral immune responses to prevent HIV-1 infection.

Other names

Mosaic HIV-1 DNA vaccineDNA-Mosaic envMosaic Env DNA